Early paxalisib TNBC responses highlighted by Kazia Therapeutics (NASDAQ: KZIA)
Rhea-AI Filing Summary
Kazia Therapeutics Limited files a prospectus supplement covering 95,110 American Depositary Shares (ADSs), which represent 47,555,000 ordinary shares, to update its existing Form F‑1 prospectus with new clinical information from a recent Form 6‑K. The update centers on a Phase 1b study of paxalisib in late‑stage metastatic triple‑negative breast cancer (TNBC) in combination with pembrolizumab and chemotherapy.
In this program, three patients with metastatic TNBC treated with paxalisib‑based regimens have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated, with most adverse events considered unlikely or unrelated to the drug and only expected, mainly mild to moderate, paxalisib‑related side effects reported at the 30 mg daily dose.
Kazia plans to activate two additional clinical sites by April 2026 and two more in mid‑2026, targeting enrollment of twelve TNBC patients by the end of 2026 and a topline data readout in early 2027, while continuing broader development of paxalisib and other oncology assets.
Positive
- None.
Negative
- None.
Insights
Early TNBC responses are encouraging but based on a very small patient set.
The company highlights preliminary results from a Phase 1b study of paxalisib combined with pembrolizumab and chemotherapy in metastatic TNBC. Among patients exposed to paxalisib‑based regimens, two in the formal trial achieved partial responses and a separate expanded‑access patient achieved a confirmed complete metabolic response on FDG PET/CT, which is notable in this hard‑to‑treat setting.
Safety so far appears manageable: approximately
The development plan includes activating two additional clinical sites by April
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-276774
PROSPECTUS SUPPLEMENT
(to Prospectus dated December 22, 2025)
95,110 American Depositary Shares representing
47,555,000
Ordinary Shares
Kazia Therapeutics Limited
This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-276774), as amended, with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on January 27, 2026 (the “January 27, 2026 Form 6-K”). Accordingly, we have attached the January 27, 2026 Form 6-K to this prospectus supplement.
This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On January 26, 2026, the last reported sale price of the ADSs on Nasdaq was $7.93 per ADS.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is January 27, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2026
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrant’s name into English)
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On January 27, 2026, Kazia Therapeutics Limited (the “Company”) issued a press release titled “Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer”. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company’s registration statements on Form F-3 (File No. 333-281937).
EXHIBIT LIST
| Exhibit | Description | |
| 99.1 | Press Release of Kazia Therapeutics Limited dated January 27, 2026 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Kazia Therapeutics Limited (Registrant) |
| /s/ John Friend |
| Name: John Friend |
| Title: Chief Executive Officer |
| Date: January 27, 2026 |
Exhibit 99.1
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Sydney, Australia, January 27, 2026; Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC).
To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program.
Clinical Highlights
| • | 2 of 2 evaluable patients enrolled in the Phase 1b trial achieved partial responses |
| • | One advanced metastatic TNBC patient achieved a confirmed complete metabolic response following re-treatment with pembrolizumab/chemotherapy plus paxalisib (under an expanded access protocol) |
| • | Responses observed in patients with visceral disease and multi-organ metastases |
| • | Median time on treatment to date is approximately 6.1 months, with all patients continuing on therapy at the time of this update |
| • | Paxalisib continues to demonstrate a generally favorable safety and tolerability profile when combined with pembrolizumab and chemotherapy at the 30 mg daily dose |
The ongoing Phase 1b trial is a multi-center, open-label, randomized study initiated in June 2025 designed to evaluate the safety, tolerability, and preliminary clinical activity of paxalisib in patients with advanced breast cancer, including TNBC, in combination with either: Pembrolizumab plus chemotherapy (current standard-of-care first-line regimen) or Olaparib (advanced breast cancer patients with BRCA mutations). Eligibility for the pembrolizumab-containing cohort required PD-L1–positive disease (CPS ≥10), consistent with standard-of-care practice in metastatic TNBC.
Patient 1 – Partial Response
A 61-year-old female with metastatic TNBC involving the left upper lobe of the lung, initiated treatment with paxalisib (30 mg daily) in combination with pembrolizumab and gemcitabine/carboplatin in June 2025. After nine cycles of therapy, serial imaging demonstrated continued tumor reduction at each assessment, culminating in a partial response by iRECIST criteria. The patient remains active on study.
Patient 2 – Partial Response with Complete Resolution of a Target Lesion
A 47-year-old female with extensively metastatic TNBC involving the lung, liver, bone, and lymph nodes, initiated treatment with paxalisib (30 mg daily) in combination with pembrolizumab and gemcitabine/carboplatin in October 2025. Following three treatment cycles, imaging demonstrated a partial response, including complete resolution of a target lung lesion and the patient remains active on study.
Patient 3 – Confirmed Complete Metabolic Response
A 44-year-old female with metastatic TNBC who had previously received pembrolizumab/chemotherapy experienced disease progression involving bone and lung metastases in early 2025. Although ineligible for the formal trial due to prior pembrolizumab exposure, the patient was re-treated beginning in June 2025 with pembrolizumab/chemotherapy plus paxalisib (30 mg daily) under physician supervision. On November 10, 2025, FDG PET/CT imaging demonstrated no evidence of active malignancy, consistent with a complete metabolic response. This complete metabolic response was confirmed on follow-up imaging in January 2026, and the patient remains on paxalisib and pembrolizumab therapy.
Paxalisib has been generally well tolerated in combination with pembrolizumab and chemotherapy. Approximately 75% of adverse events (AEs) were assessed as unlikely or unrelated to paxalisib. The paxalisib-related AEs were expected and predominantly mild to moderate, consistent with prior studies. At the 30 mg daily dose, one case of Grade 1 hyperglycemia has been observed, requiring no intervention. Two serious adverse events (SAEs) have been reported to date, both deemed unrelated to paxalisib.
Following an initial targeted site activation phase designed to ensure rigorous protocol execution and informed by encouraging early clinical signals from the first patients treated, the Company expects to activate two additional clinical sites by April 2026, with two further sites planned for mid-2026. Kazia continues to anticipate the targeted enrollment of twelve TNBC pts target by the end of 2026 and topline data readout in early 2027
Kazia is also evaluating paxalisib in additional breast cancer populations, including earlier-stage TNBC and hormone receptor–positive, HER2-negative (HR+ / HER2-) breast cancer, where dysregulation of the PI3K/mTOR pathway is well established. Paxalisib’s oral, once-daily administration offers a potentially convenient treatment option with minimal incremental burden to patients and clinical sites, an important consideration as the Company explores expansion into broader breast cancer populations. The Company will provide updates as these programs advance.
“While these observations represent a preliminary read from ongoing studies, the consistency and depth of responses we are seeing including tumor regression across multiple metastatic sites and a complete metabolic response are highly encouraging,” said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therapeutics. “Confirmed complete responses in metastatic triple-negative breast cancer are exceedingly rare, particularly in patients who have already progressed on standard therapies. These early data reinforce our belief that paxalisib has the potential to meaningfully enhance the activity of existing immunotherapy-based regimens, and we look forward to generating additional clinical and translational insights throughout the year.”
For investor and media, please contact Mike Moyer, Managing Director LifeSci Advisors LLC, mmoyer@lifesciadvisors, +1-617-308-4306.
About Kazia Therapeutics
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary
central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class nuclear PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, currently in preclinical development. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.
Forward-Looking Statements
This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, the plan to activate additional clinical sites for the Phase 1b study in 2026, the anticipated completion of enrolment in the Phase 1b clinical trial in the fourth quarter of 2026, the anticipated topline data readout in early 2027, the potential of paxalisib’s oral, once-daily administration to offer a convenient treatment option with minimal incremental burden to patients and clinical sites, the opportunities of evaluating paxalisib in additional breast cancer populations, and the potential benefits of paxalisib. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia’s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
FAQ
What does Kazia Therapeutics (KZIA) register in this prospectus supplement?
The prospectus supplement relates to 95,110 American Depositary Shares (ADSs) of Kazia Therapeutics Limited, representing 47,555,000 ordinary shares, and updates the existing Form F‑1 prospectus with new information from a January 27, 2026 Form 6‑K.
What new clinical data does Kazia Therapeutics (KZIA) disclose for paxalisib in TNBC?
The company reports that three patients with metastatic triple‑negative breast cancer treated with paxalisib‑based regimens have shown meaningful responses, including two partial responses in the Phase 1b trial and one confirmed complete metabolic response in a patient treated under an expanded access program.
How well tolerated is paxalisib in the ongoing Phase 1b TNBC study?
Paxalisib in combination with pembrolizumab and chemotherapy has been generally well tolerated. About 75% of adverse events were assessed as unlikely or unrelated to paxalisib, with expected, mostly mild to moderate paxalisib‑related side effects at the 30 mg daily dose and one case of Grade 1 hyperglycemia requiring no intervention.
What is the design of Kazia Therapeutics’ Phase 1b breast cancer trial with paxalisib?
The ongoing Phase 1b trial is a multi‑center, open‑label, randomized study in advanced breast cancer, including TNBC, evaluating paxalisib in combination with either pembrolizumab plus chemotherapy or olaparib. For the pembrolizumab cohort, patients must have PD‑L1–positive disease (CPS ≥10), consistent with standard practice in metastatic TNBC.
What future milestones does Kazia Therapeutics (KZIA) outline for the TNBC paxalisib study?
Kazia plans to activate two additional clinical sites by April 2026 and two more in mid‑2026, aims to enroll twelve TNBC patients by the end of 2026, and anticipates a topline data readout from the Phase 1b trial in early 2027.
What other cancer indications is Kazia Therapeutics pursuing with paxalisib and its pipeline?
Beyond TNBC, paxalisib is being evaluated in glioblastoma, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma. Kazia is also developing EVT801, a VEGFR3 inhibitor, and NDL2, a nuclear PD‑L1 protein degrader program, both aimed at oncology indications.
